News & Updates

The investigational combination of doravirine plus islatravir (DOR/ISL)—a fixed-dose, once-daily oral antiretroviral therapy (ART) regimen that does not rely on integrase strand-transfer inhibitors (INSTIs)—is shaping up to be a promising alternative in the management of HIV, showing noninferiority to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in individuals initiating treatment for the first time and maintaining virologic suppression in those switching from various ART regimens, as shown in three phase III studies presented at CROI 2026.

A single-tablet regimen (STR) combining bictegravir and lenacapavir (BIC/LEN) was noninferior to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in maintaining virologic suppression among people with HIV (PWH) who are virologically suppressed, according to the ARTISTRY-2 trial presented at CROI 2026.

In adolescents with well-controlled HIV, switching from an oral antiretroviral therapy (ART) regimen to the long-acting injectable cabotegravir plus rilpivirine combination appears to be not only safe and efficacious in maintaining viral suppression but also strongly favoured, according to the end-of-study data from the phase I/II IMPAACT 2017 study.

Treatment with either metformin or ursodeoxycholic acid (UDCA) falls short of improving recovery from postacute sequalae of SARS-CoV-2 infection (PASC), a study has shown.

Interventions by transitions of care (TOC) pharmacists have significantly shortened discharge days of therapy (DOT) and total DOT for community-acquired pneumonia (CAP) therapy, reports a study.